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  2[1] Executive summary 
 
Balloon angioplasty and coronary stent deployment are powerful techniques in the treatment of 
individuals with advanced coronary artery disease.  Recent advancements have led to the 
development of drug-eluting stents designed to release a drug polymer that inhibits restenosis, a 
bodily defense mechanism characterized by tissue ingrowth and reblockage of the artery.  The 
stent is coated with an anti-cancer or immunosuppressive drug that diffuses through the 
surrounding tissues over a critical period of time.  In this study, diffusion of the drug Rapamycin 
was modeled using computer-aided design software.  Analysis was performed in order to 
determine the concentration profile of the drug at various time intervals.  The stent geometry was 
reduced to six concentric rings of 1.5 mm width spaced 1.5 mm apart, resulting in a total stent 
length of 16.5 mm.  Diffusion was modeled from only one of these rings and conclusions were 
drawn considering the global diffusion from multiple rings of this type.  A graded mesh was 
generated in GAMBIT, and simulations were executed in FIDAP to assess the drug 
concentration as a function of several input parameters.  It was concluded that the drug reaches 
48 μg/m
3, within a defined therapeutic concentration range of 40-60 μg/m
3, after about nine 
months at a penetration depth of 0.015 mm.  This indicates that after nine months the first tissue 
layer surrounding the coronary lumen, also known as the intima, is saturated with drug at 
concentrations necessary for the prevention of restenosis.  Sensitivity analysis was performed to 
test the stability of our solution and to assess factors which may affect the diffusion process.  It 
was found that the concentration of Rapamycin was most sensitive to a change in diffusivity of 
Rapamycin in the intimal tissue layer, whereas the drug concentration was less sensitive to 
changes in the stent diffusivity and variance in initial concentration of drug immobilized in the 
stent. 
 
[2] Introduction and Design Objectives 
 
2.1 Introduction 
 
Coronary artery disease is a result of plaque buildup on the interior walls of arteries that supply 
blood to the heart.  As buildup increases, the area within the artery that allows for blood flow 
decreases.  The decrease in flow allows clots to form on the surface of the wall and leads to, in 
the majority of cases, a heart attack.  Risk factors for this disease include, but are not limited to, 
smoking, high blood pressure, high cholesterol, diabetes, obesity and physical inactivity.  
Coronary artery disease is the most common heart disease and the leading cause of death in the 
United States and can be attributed to over 500,000 deaths a year and thus should not be taken 
lightly. 
Methods to treat coronary artery disease focus on widening the flow area of the artery by 
pushing the plaque towards the arterial walls.  The first procedure was performed in 1977 and 
involved a balloon catheter that was navigated into the affected artery through a small incision in 
the leg or the arm of the patient.  Once the destination was reached, the doctor would then inflate 
the balloon to widen the artery.  This procedure would relieve the patient of the chest pain for 
several months, but over 30% of all coronary arteries would begin to close up again, a 
phenomenon known as restenosis.  Once restenosis has occurred, the patient would either find 
  3himself in the same situation as before the procedure or have to endure an emergency bypass 
graft surgery, depending on the amount of time that has elapsed since the initial surgery. 
In 1986 the metal stent was introduced to help lower the rate of restinosis in balloon 
angioplasty patients.  Coronary stents are cylinders made of metal mesh that is almost analogous 
to a metal fence.  They are placed on a separate balloon catheter that is inserted after the first 
balloon angioplasty.  Once the artery is widened by the first procedure, the balloon catheter 
containing the stent is inserted and opened at the location of the plaque buildup.  With this stent 
in place it was believed that the artery would remain widened, however, restinosis still occurred 
in 25% of the cases, resulting in a necessity of a repeat procedure.  It was through investigating 
the restinosis that occurred after stent injection that doctors concluded that restinosis was not just 
a second buildup of plaque, but rather scar tissue formation after angioplasty.  In the specific 
case of the metal stent, the body responded to the foreign object by treating it as a wound and as 
an outcome scar tissue grows around the metal and into the artery.  The physicians could now 
use this information to help battle restinosis through a variety of different methods with one of 
the more successful ones being drug delivery by the sent itself. 
Drug-eluting stents are coated with a drug that interrupts the restinosis process.  By placing 
this stent into the body, it not only opens the artery, but also prevents the scar-tissue formation 
that occurs concurrently with angioplasty.  This is a fairly new procedure with the first FDA 
approval on April 24, 2003, however the results of recent studies look promising.  Out of 1,000 
patients that were enrolled in a study, only 3.9% in the drug coated group experienced restinosis, 
compared to 35.4% that were given the bare metal stents. 
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Figure 2.1: This is an illustration of an angioplasty procedure and the results obtained with a stent that does not 
elute drugs.  Without a drug-eluting stent, restenosis was found to occur by building plaque back up within the 
spaces of the stent, thus, resulting in a need for a drug to prevent restenosis. 
 
2.2 Problem Schematic 
 
The coronary artery was modeled as having a stent embedded in two tissue layers: intima and 
adventitia.  The stent geometry was simplified to six concentric rings with a square-cross section.  
Each ring was 1.5 mm in width and spaced 1.5 mm apart (see Appendix A).  A total of six rings 
were used to model an actual stent of length 16.5 mm.  Diffusion was only modeled from one of 
  4these rings and the final solution was multiplied to include the global diffusion from all six rings.  
The coronary artery was modeled as a right cylindrical element with concentric rings that were 
axi-symmetric about the center lumen.  As shown in Appendix A.1.1, the problem contained 
three regions: the stent region, the intima region and the adventitia region.  The lumen was 
excluded from the geometry.  Instead, a convective term was specified at the lumen-intima/stent 
interface to mimic blood flow.  The problem was transient with an initial concentration at the 
stent and a convection term due to blood flow at the lumen interface.  See Appendix A for the 
governing equation, boundary and initial conditions. 
 
2.3 Objectives 
 
By modeling the interaction of the drugs in the stent with the tissue in the artery, we wanted to 
accurately model and determine the time at which a steady-state concentration was reached and 
the time at which a therapeutic concentration was maintained in the intima.  An additional 
objective was to determine the sensitivity of the concentration of Rapamycin in the intima to 
varying parameters, as discussed in the sensitivity analysis.  Additionally, accurately modeling a 
complex biomedical physical situation within the constraints of Fidap and Gambit was a main 
objective. 
 
[3] Results and Discussion 
 
3.1 Major Findings 
 
The simulation was run at time intervals of 1 day, 1 week, 1 month, 2 months, 6 months, and 2 
years to evaluate solution convergence.  Contour plots are shown in Figure 3.1 and 3.2; a 
corresponding graph of the concentration versus time is shown in Figure 3.3.  From these figures 
it can be seen that the solution converges just before time = 25,000,000 seconds.  This is 
equivalent to about 9 months.  Our goal was to find the time at which a therapeutic concentration 
range of 40-60 μg/m
3 was reached at the intima/adventitia interface above the center of the stent 
(concentration plots were derived for the node at x = 0 and y = 1.53 mm)
 7.  We made the 
assumption that the entire intima had to be at a therapeutic concentration in order to prevent 
restenosis.  Also, assuming that each concentric ring was spaced a distance of one ring width 
apart, the entire intima would be saturated with therapeutic drug concentration when node 
(0,1.53) was saturated.  Figure 3.3 shows that a single ring reaches a drug concentration of about 
8 μg/m
3 after this time.  Considering the cumulative effect of all six rings, the intima is saturated 
with a total concentration of 48 μg/m
3 after nine months.  This value is within the range of our 
therapeutic concentration.  It is thus concluded that a Rapamycin-eluting stent of diffusivity D = 
1 x 10
-13 m
2/s and initial drug concentration cs = 170 μg/m
3 will generate a sufficient amount of 
medication to prevent restenosis in a period slightly less than a year.  All properties, boundary 
conditions, initial conditions, governing equations are stated in Appendix A.  
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Figure 3.1: A contour plot of the entire geometry after the solution has converged in less than a year.  Regions far 
from the stent show a zero concentration (royal blue).  This means that our simplified geometry was large enough to 
encompass the regions of changing concentration.  From this contour plot, it is apparent that we could reduce the 
geometry size further in an attempt to decrease the computing time.   
 
time = 1 day  time = 1 week  time = 1 month 
time = 2 months  time = 6 months  time = 2 years 
 
 
Figure 3.2: Contour plots of the drug concentration for varying time intervals of time = 1 day, 1 week, 1 month, 2 
months, 6 months, and 2 years.  The contour regions shown are for a reduced geometry emphasizing the regions of 
greatest concentration gradients.  After 6 months it is evident that the concentration profile has almost reached a 
steady state as it is very similar to the contour plot for time = 2 years. 
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Figure 3.3: Concentration plot of the drug concentration for a node taken at the intima/adventitia interface.  The 
de 
he contour plot is as expected, with uniform diffusion of the drug from the highest 
e cross 
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igure 3.4 shows the concentration plot for several randomized nodes over time.  This graph 
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drug concentration is shown to converge after a time of about 9 months.  The final concentration at the plotted no
is about 8 μg/m
3 for a single ring.  This means that a total concentration of 6 x 8 μg/m
3 = 48 μg/m
3 is in the arterial 
region after 9 months. An initial drug concentration of 170 ug/m
3 in the stent was used.  
 
T
concentration region in the stent diffusing into the tissues.  Our assumption of a squar
section of the ring element does not matter because the concentration profile assumes a radial
distribution as the solution converges over time. The concentration plot is also as expected.  
Rapid concentration gradients occur during the first few months following stent implantation
fact, a linear region exists before time = 10,000,000 seconds, or during the first four months.  
From then on, the concentration is increasing in the tissues at a decreasing rate.  It is not until 
nine months that the drug has reached its maximum concentration within the tissue regions.  T
model does not take into account the degradation of the drug over time because the complexity 
of Rapamycin pharmacokinetics have made studies on degradation rates for long time periods 
relative unfeasible.  After nine months, the drug concentration will decrease but restenosis will
still have been prevented.  This is assumed because the drug was at an optimum concentration 
during the critical time at which restenosis is likely to occur.   
 
F
further demonstrates that a solution is converging after a non-dimensionalized time of 5.  This
equivalent to slightly less than a year, as expected.  Figure 3.5 shows a similar concentration plot 
for several different nodes within the adventitia region.  The bluer lines toward the top of the 
graph are closet to the stent.  Subsequent lines show nodal concentrations at linearly increasin
distances from the stent, showing that concentrations were smaller further from the drug source. 
  7This figure also shows that the greatest initial concentration gradients occurred in regions 
closest to the stent, showing that our model approximates physical reality. 
 
 
Figure 3.4: Concentration plot of the drug concentration for randomized nodes.  The drug concentration is 
shown to converge for all regions in a little less than a year.  It can be assumed that lines with large initial 
concentration gradients occur closer to the stent.  Time in this plot is non-dimensionalized. 
 
 
 
Figure 3.5: Concentration plot of the drug concentration for a several nodes within the adventitia.  
Concentration lines are taken at nodes at a linearly increasing distance from the stent with the red lines 
furthest from the stent and the blue lines closet to the stent.  It can be seen that regions closer to the stent 
have higher concentrations as well as an increased concentration gradient during initial times.  Again, all 
regions converge in a little under a year.  Time in this plot is non-dimensionalized.   
Figure 3.6: The region of nodes for Figure 3.5 were picked from the highlighted region, which consists of the 
adventitia tissue.  Nodes closest to the stent had higher concentrations of Rapamycin, as seen in Figure 3.5. 
 
3.2  Sensitivity Analysis 
 
Because drug-eluting stents are complex implanted medical devices, simulation of the elution of 
Rapamycin is influenced by many factors, such as geometry of the stent, diffusion through 
heterogeneous materials, and chemical properties of the released drug.  In order to determine the 
validity of our solution and the potential range of results that could be obtained by varying input 
parameters, we performed sensitivity analysis for variations in initial drug concentration, 
diffusivity, and reaction rate, all of which are relevant for effective stent design.  Large variations 
were found for each parameter in the literature; this was further analyzed in Appendix C.  For 
our analysis of the solution sensitivity to various parameters, it was assumed that a maximum of 
20% error was inherent in the values used in the final solution. 
 
3.2.1 Variation of Initial Concentration of Rapamycin in Stent 
 
Sensitivity analysis was performed on initial drug concentration because wide variation in drug 
concentration was found in manufactured drug-eluting stents due to differences in a) stent length 
based on medical necessity due to initial area of arteriolar blockage, b) stent radius based on the 
gender and age of the angioplasty patient, and c) nature of the anti-restinosis drug based on 
variable therapeutic and toxic concentrations.  For our simulation, the initial, homogenous 
concentration of Rapamycin in the stent was assumed to be 170 µg/m
3.
7  Figure 3.7 shows that 
varying the initial concentration of Rapmycin in the stent yielded a variation in concentration in 
the intima of +10.5% to -8.5%.  Therefore, the simulation is moderately sensitive to the initial 
concentration of Rapamycin immobilized in the stent. 
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Figure 3.7: Plot of concentration versus time for our original initial concentration of Rapamycin in the stent, a 
concentration 20% higher, and a concentration 20% lower.  The final time for the figure is one month, which is why 
a steady-state concentration is not reached. 
 
3.2.2 Variation of Diffusivity of Rapamycin in Intima 
 
Variation of diffusivity of Rapamycin in the intima was our next sensitivity analysis.  Diffusivity 
values were increased and decreased by 20% to test the sensitivity of our model to this 
parameter, as widely varying diffusivity values for the drug in the intima were found for real-life 
situations (see Appendix C for further discussion).  As shown by figure 3.8, it was found that this 
parameter had the greatest effect on the final concentration of Rapamycin in the intima, likely 
because it dictates how far and how much of the drug will travel through the intima in a specified 
amount of time.  A higher diffusivity will result in more drug traveling further, which will result 
in a greater concentration of drug reaching further into the tissue.  Because our design is so 
sensitive to this parameter, there must be special attention paid to choosing a biologically-
accurate diffusivity value for the intima. 
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Figure 3.8: Plot of concentration versus time for our original diffusivity of Rapamycin in the intima, a diffusivity 
20% higher, and a diffusivity 20% lower. The final time for the figure is one month, which is why a steady-state 
concentration is not reached. 
 
3.2.3 Variation of Diffusivity of Rapamycin in Stent 
 
Our final sensitivity analysis was varying the diffusivity of Rapamycin in the stent.  We chose to 
vary this parameter due to the large range of diffusivity values found in various literature 
references.  Additionally, because we chose to model the stent as a homogeneous polymer rather 
than a polymer-coated metal stent, sensitivity to a range of diffusivity values was a concern.  As 
shown in Figure 3.9, this parameter was the least-sensitive to small changes.  This is likely 
because the stent diffusivity is currently relatively large; small changes will not greatly inhibit 
drug transfer to the intima.  However, as shown in Figure 3.9, higher diffusivities still yield 
higher drug concentrations in the intima for short times. 
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Figure 3.9:  Plot of concentration versus time for our original diffusivity of Rapamycin in the stent, a diffusivity 
20% higher, and a diffusivity 20% lower. The final time for the figure is one month, which is why a steady-state 
concentration is not reached. 
 
3.3 Results vs. Expected Results 
 
For the most part, our results reflected a realistic biological drug-diffusion process as anticipated.  
The drug diffusion assumed to be radial regardless of the fact that we modeled the stent thickness 
as a square.  The drug concentration at deeper points in the tissue was less than those closer to 
the stent.  The problem also reached steady state after a period of about 9 months, indicating that 
the drug concentration remains effective during the period of highest risk of restenosis.  
  However, there were also many unexpected results such as the drug accumulating in 
areas rather than staying at the same concentration.  As seen from Figure 3.2, the drug 
accumulated around the stent while diffusing outwards.  This unexpected result could be due to 
the fact that we assumed the drug elimination, drug binding, partition coefficients, and pressure 
gradients in the artery to be negligible.  Had we included these parameters, the drug would not 
have simply accumulated in certain areas, but rather stayed at a steady state concentration, 
indicating the drug was both diffusing and being eliminated from the area. 
  Another unexpected result was that initially, it appeared that there was no change in drug 
concentration at the convective boundary.  Simply looking at the contour plots obtained, one 
would assume that there was no real difference in concentration at the lumen/intima interface.   
Since our convective coefficient (0.915) is so small, it acts like an insulating boundary condition 
rather than a convective condition.  When zooming into the contour plot, there does appear to be 
a change of approximately 2% at the periphery of the semicircular concentration gradient.  
 
  12[4] Conclusions and Design Recommendations 
 
4.1 Conclusion 
 
Using all original parameters, it is concluded that the Rapamycin drug reaches a concentration of 
48 μg/m
3  in the entire intima surrounding the stent after nine months.  This is within the 
therapeutic concentration range.  The solution is obtained using a drug diffusivity of D = 1 x 10
-
13 m
2/s, a tissue diffusivity of D = 1 x 10
-14 m
2/s, and an initial drug concentration of cs = 170 
μg/m
3
. 
  This concentration will effectively prevent restenosis during the first year after stent 
deployment, the critical time for which tissue ingrowth and other immune responses are most 
likely to occur.  
 
4.2 Realistic Constraints 
 
When creating our geometry, a number of simplifications were made and must be addressed.  
The first, and most drastic simplification we made is disregarding the blood velocity in the 
artery.  When we first started, we modeled a velocity profile in the lumen.  However, due to 
small diffusivity values and constraints due to non-dimensionalization, the velocity profile was 
found to be too complex to implement.  Therefore, the fluid flow was replaced by a convective 
boundary layer at the lumen/intima interface. 
Other major simplifications arose from the fact that the arterial geometry, as well as the 
surrounding heart geometry, is very complex.  In the artery itself, there are a total of five 
different tissue layers, whereas we modeled two tissue layers that incorporated all five.  Also, 
depending on many factors, including age, gender, and body size, the diameter of the artery may 
vary greatly from person to person.  This variation can result in highly variable blood velocities 
in the artery, which can be translated into different convective terms in our model.  Additionally, 
branching in arteries, which cannot be easily modeled, may affect the blood velocity. 
When creating our stent model, we used simplified concentric circles, whereas 
manufacturing companies utilize much more complex three-dimensional geometries, which 
could affect the true concentration of Rapamycin in the intima.  However, these complex 
geometries are nearly impossible to duplicate as an axi-symmetric geometry in GAMBIT, and 
we feel that our simplified model did not produce significant deviation from experimental 
results, meaning that our geometry simplification was not a major source of error. 
  Metal is currently the only support material for clinically-approved stents; because of 
this, the stents must permanently remain in the body.  Due to the relatively adolescent nature of 
drug-eluting stents, long-term effects of a permanent stent in the artery have not been explored in 
depth.  Past permanent implants have resulted in immune responses such as tissue ingrowth into 
the stent, particulate debris of the stent into the blood and clot formation around the foreign 
object
8.  These responses can be greatly reduced if the stent were to degrade after prevention of 
restinosis has been achieved.  Biodegradable polymer stents are currently being developed to 
help solve this problem; these stents will remain in the body as long as it is needed, then safely 
disintegrate into the blood and surrounding tissues.  However, one barrier in using a 
biodegradable polymer stent is that the polymer is not strong enough to withstand shear forces 
due to arterial blood flow.  Hopefully, in the near future, long-term sustainability can be achieved 
through a temporary implant.  For further elaboration on solution constraints, see Appendix C. 
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4.3 Design Recommendations 
 
We recommend that stents should be designed to hold an initial concentration of 6 x 170 μg/m
3, 
which is 1020 μg/m
3.  This initial concentration has been shown to effectively prevent restenosis 
during the critical first year of post-implantation. We would advise use of Rapamycin instead of 
Paclitaxel, due to the potential toxicity of Paclitaxel
5.  For design, we would also recommend a 
stent composition that would yield lower values of stent diffusivity to provide a better drug 
distribution in time because the concentration level in the tissue would be higher.  Additionally, a 
slower drug release process may decrease the amount of drug that is lost to blood flow or 
diffused to deeper tissues that do not need medication. 
 
[5] Appendices 
 
Appendix A – Mathematical Statement of Problem 
 
A.1 Geometry and Schematic 
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       Circular rings spaced distance 0.015 mm apart 
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  14A.1.1 Geometry 
x = -10 mm   x = 0.0075 mm    x = -0.0075 mm    x = 10 mm 
y = 1.53 mm 
y = 1.515 mm 
y = 1.5 mm 
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A.1.2 Governing Equation 
 
Species Equation: 
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A.2 Input Parameters 
 
Variable Value  (Dimensional) Value*  (Non-dimensional) 
Diffusivitystent
7 1.0 x 10
-13 m
2/s 10 
Diffusivityadventitia
10 1.0 x 10
-14 m
2/s 1 
Diffusivityintima
10 1.0 x 10
-14 m
2/s 1 
Duration of Simulation (tfinal)  6.31 x 10
7 s (2 years)  11.2 
Time Step (dt)  1 s  0.5 
Mass transfer coefficient (hm)
10
1.22 x 10
-11 m/s  0.915 
 
  15Methods of Non-Dimensionalization 
 
There was a need to non-dimensionalize our parameters and geometry because our values were 
extremely small.  Since Fidap could not handle such small parameters there was a need to non-
dimensionalize which allowed us to work on a bigger scale. 
 
•  Characteristic Length:    L =  m 
6 10 * 5 . 7
−
 
 
x = 1   x = -1   x = 13.33   x = -13.33  
y = 33.33  
y = 24  
y = 22  
y = 20  
 
 
 
•  Stent Diffusivity:      10
D
D
* D
Adventita
Stent
stent = =  
•  Adventitia Diffusivity:    1
D
D
* D
advent
advent
advent = =  
•  Duration of Simulation:    (tfinal)* =  2 . 11
2 =
L
D t advent final  
•  Mass transfer coefficient:   hm* =  915 . 0
*
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advent
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D
h L
 
 
 
 
 
 
A.3 Initial and Boundary Conditions 
 
A.3.1 Initial Conditions 
 
Ctissue0  = 0 
Cstent0 =170 μg/m
3  
 
  16A.3.2 Boundary Conditions 
 
Lumen-stent/intima interface: 
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Convection due to blood flow 
Species flux = 0 
Species flux = 0 
Species flux = 0 
Initial drug concentration = cs
Initial drug concentration = 0 
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Appendix B -- Solution Details 
 
B.1 Solver Statements 
 
B.1.1 PROBLEM Statement 
PROB (AXI-, ISOT, NOMO, TRAN, LINE, FIXE, NEWT, INCO, SPEC = 1.0) 
Define Models FIINP Reason
Geometry Type  Axi-symmetric (AXI-)  Only one calculation was necessary 
due to our geometry having 
symmetry about an axis 
Temperature 
Dependence 
Isothermal (ISO T)  Problem was independent of 
temperature 
Viscous Dependence  Momentum Turned Off 
(NOMO) 
The blood flow was not modeled, 
therefore there was not fluid flow in 
the problem 
Time Dependence  Transient (TRAN)  Problem was dependent on time 
Deforming Boundary  Fixed (FIXE)  The surface was unchanging 
Convective Term  Linear (LINE)  No convection 
Fluid Type  Newtonian (NEWT)  There was no fluid flow 
Flow Regime  Incompressible (INCO)  Since there was no fluid flow, this 
term is not relevant  
Species Dependence  Species Present 
(SPEC=1.0) 
The mass species present was the 
drug in the stent 
 
B.1.2 SOLUTION Statement 
SOLU (S.S. = 50, VELC = 0.100000000000E-02, RESC = 0.100000000000E-01, 
       SCHA = 0.000000000000E+00, ACCF = 0.000000000000E+00) 
Commands FIINP  Reason 
Solution Method  Successive substitutions of 
50 iterations (S.S.=50) 
Default setting 
 Velocity  Convergence 
(VELC=0.100E-02) 
Default setting 
 Result  Convergence 
(RESC=0.100E-01) 
Default setting 
 Solution  Change 
(SCHA=0.00) 
Solution check was disabled
Relaxation Factor  Relaxation Factor 
(ACCF=0.00) 
There was no relaxation 
factor incorporated in the 
our problem 
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B.1.3 TIME INTEGRATION Statement: 
TIME (BACK, FIXE, TSTA = 0.000000000000E+00, TEND = 0.4608, 
       DT = 0.100000000000E-02, NSTE = 5000) 
Command FIINP  Reason 
Time Integration  Backward (BACK)  Used for transient analysis 
Time Stepping Algorithm  Fixed (FIXE)  Increment of time is 
unchanging 
Starting Time  Start Time (TSTA=0.00)  Starting time is at 0 seconds 
End Time  End Time (TEND=0.4608)  Ending time is at 1 month 
non-dimensionalized 
Time Increment  Time Step Size  
(DT=0.10E-02) 
Size of time increment 
Number of Time Steps  Number of Time 
Steps(NSTE=5000) 
The maximum number of 
discrete time integration 
steps 
 
B.2 Mesh 
 
B.2.1 Plot of Mesh 
 
Figure B1: A plot of the element mesh, containing 19,000 elements. The mesh density is greater nears the stent, 
where the greatest change in drug concentration will occur. 
 
 
 
 
 
 
  19B.2.2 Plot of Node Numbers: 
 
Figure B2: A plot of the element mesh with node numbers labeled. 
 
B.2.3 Mesh Convergence 
 
To ensure that our mesh converged, we decided to take the drug concentration at a particular 
node inside the intima at the same time for six different meshes.  Our initial mesh was not 
sufficient, because there was a large difference in concentration at the node for a finer mesh. We 
continued to refine our mesh until we obtained the same concentration value at a single node for 
the current and more refined mesh.  At 19,000 elements a concentration of about 0.016μg/mm
2 
and at a mesh with 28,180 elements, the same concentration value was obtained.  Therefore, we 
considered our mesh to converge at 19,000 elements and then used this refined mesh to solve. 
Ensuring that our mesh converges results in a solution that is independent of the mesh. 
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Figure B3: Mesh convergence study for six mesh configurations at a single node inside the tissue. 
 
B.3 FIINP File 
//FICONV(NEUTRAL,NORESULTS,INPUT) 
/  INPUT(FILE= "convect.FDNEUT") 
/  END 
/  *** of FICONV Conversion Commands 
/TITLE 
/ 
/ ***  FIPREP  Commands *** 
/ 
FIPREP 
PROB (AXI-, ISOT, NOMO, TRAN, LINE, FIXE, NEWT, INCO, SPEC = 1.0) 
PRES (MIXE = 0.100000000000E-34, DISC) 
EXEC (NEWJ) 
SOLU (S.S. = 50, VELC = 0.100000000000E-02, RESC = 0.100000000000E-01, 
  21       SCHA = 0.000000000000E+00, ACCF = 0.000000000000E+00) 
 TIME (BACK, FIXE, TSTA = 0.000000000000E+00, TEND = 0.4608, 
       DT = 0.100000000000E-02, NSTE = 5000) 
 OPTI (SIDE) 
 DATA (CONT) 
 PRIN (NONE) 
 POST (RESU) 
 SCAL (VALU = 1.0) 
 ENTI (NAME = "drugstent", SOLI, PROP = "blood", SPEC = 1.0, 
       MDIF = "C1_drugstent") 
 ENTI (NAME = "adventitia", SOLI, PROP = "mat1", SPEC = 1.0, 
       MDIF = "C1_adventitia") 
 ENTI (NAME = "intima", SOLI, PROP = "mat2", SPEC = 1.0, MDIF = "C1_intima") 
 ENTI (NAME = "topadventitia", PLOT) 
 ENTI (NAME = "rightadvent", PLOT) 
 ENTI (NAME = "leftadvent", PLOT) 
 ENTI (NAME = "leftint", PLOT) 
 ENTI (NAME = "rightint", PLOT) 
 ENTI (NAME = "botstent", ESPE, MSPT = "botstent") 
 ENTI (NAME = "topstent", PLOT) 
 ENTI (NAME = "rightstent", PLOT) 
 ENTI (NAME = "leftstent", PLOT) 
 ENTI (NAME = "toplumen", ESPE, MSPT = "toplumen") 
 ENTI (NAME = "topintima", PLOT) 
 DIFF (SET = "C1_drugstent", CONS = 10.0) 
 DIFF (SET = "C1_adventitia", CONS = 1.0) 
 DIFF (SET = "C1_intima", CONS = 1.0) 
 SPTR (SET = "botstent", CONS = 0.915, REFS = 1.0, POWE = 1.0) 
 SPTR (SET = "toplumen", CONS = 0.915, REFS = 1.0, POWE = 1.0) 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "topadventitia") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "rightadvent") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "leftadvent") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "leftint") 
 BCFL (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "rightint") 
 ICNO (SPEC = 1.0, CONS = 170.0, ENTI = "drugstent") 
 ICNO (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "adventitia") 
 ICNO (SPEC = 1.0, CONS = 0.000000000000E+00, ENTI = "intima") 
 EXTR (ON, AFTE = 25, EVER = 15, ORDE = 2, NOKE, NOFR) 
END 
/  *** of FIPREP Commands 
CREATE(FIPREP,DELE) 
CREATE(FISOLV) 
PARAMETER(LIST) 
 
 
 
  22Appendix C – Sensitivity of Rapamycin Concentration in Intima to 
Real-World Parameters 
 
Because a very large range of parameter values can be found for currently manufactured and 
clinically-tested drug-eluting stents, in addition to our sensitivity analysis, we performed further 
comparison analysis to show the effect of using a larger range of initial concentrations, different 
anti-restinosis drugs, and binding patterns in the arterial wall. 
 
Highly Variable Parameters  Range in Literature  Value Used in Solution 
1.  Initial Concentration of 
Rapamycin Immobilized in Stent
7
Low
4: 5 μg/m
3 
High
1: 196 μg/ m
3
170 μg/m
3
2.  Diffusion of Rapamycin through 
Intima (due to drug type and tissue 
binding)
10 
Low
3: 1.0 x 10
-13 m
2/s 
Table C.1: Variation in parameters affecting steady-state Rapamycin concentration in the intima 
High
3: 4.87 x10
-12 m
2/s  
1.0 x 10
-14 m
2/s 
3.  Stent diffusivity
10 Low
1: 1.0 x 10
-16 m
2/s 
High
1: 1.0 x 10
-10 m
2/s 
1.0 x 10
-13 m
2/s 
 
C.1  Influence of Initial Concentration of Rapamycin Immobilized in Stent 
 
Figure C.1 illustrates the significant difference in Rapamycin concentration profiles in the 
intima.  While each initial concentration reaches a steady-state concentration after approximately 
the same time interval, the higher concentrations reach a therapeutic concentration more rapidly, 
but have a higher risk of reaching toxic levels.  While small variations in initial drug 
concentration, as shown by the initial sensitivity analysis, did not greatly affect concentration 
profiles, considerable changes were found for the large variance found in studies of drug-elution 
from Rapamycin-coated stents. 
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Figure C.1. Plot of concentration versus time for three widely different initial concentrations found in published 
drug-eluting stent literature for a two-year simulation period. 
  23C.2  Influence of Drug Diffusivity in Arterial Tissue 
 
Drug diffusivity through the intima was an extremely variable parameter in this simulation, and 
experiment data suggests drug type and tissue-binding effects greatly affect the effective drug 
diffusivity. 
 
C.2.1  Drug Type Effects on Diffusivity  
 
Two major drugs are currently utilized in drug-eluting stents: Paclitaxel and Rapamycin.  Both 
compounds have similar molecular masses (1 kDa), solubilities of 6 g/mL, and are both 
hydrophobic
5, leading to similar elution profiles.  However, due to the slight differences in 
molecular weight and hydrophobicity, Paclitaxel and Rapamycin have slightly different 
diffusivities in tissue.  As shown by Figure C.2.1, change in diffusivity based on the differences 
found between Paclitaxel and Rapamycin had virtually no effect on the solution.  Therefore, any 
error in diffusivity values due to approximating Paclitaxel data as Rapamycin data would result 
in a similar drug concentration at a particular tissue depth. 
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Figure C.2.1. Plot of concentration versus time for Rapamycin (our original solution) and Paclitaxel, a similar anti-
restinosis drug, for a two-year simulation period. 
 
C.2.2  Tissue Binding Effects on Diffusivity 
 
Specific binding to intracellular receptors in the intima differs greatly between Rapamycin and 
Paclitaxel, creating dissimilarities between the accumulation of Paclitaxel and Rapamycin in 
distinct areas of the vascular wall.  Optimally, drug concentrations should peak in the intimal 
layer of the vascular wall
2.  While Rapamycin distributes equally within the vascular layers, 
Paclitaxel accumulates in the adventitia, potentially because Paclitaxel has specificity to 
microtubules, while Rapamycin shows similar specific binding to FKBP12, which have different 
tissue distributions in the coronary artery
5.  A partition coefficient k >> 1 has been found for 
Paclitaxel
3; however, we were unable to implement this due to limitations inherent in FiDAP.  
  24Studies have shown that Paclitaxel partitions significantly in the adventitia, while Rapamycin is 
more evenly distributed throughout the arterial wall.  This is a major point of concern for clinical 
implementation, as uneven binding of Paclitaxel could lead to toxic effects due to abnormally 
high concentrations in the tissue. 
 
C.3 Stent Composition Effects on Diffusivity of Rapamycin in Stent 
 
Because many different polymer types are used in drug-eluting stents, it was important to 
consider the variation in diffusivity of the stent.  Due to constraints arising from a lack of fluid 
flow and differing stent compositions, an optimal solution would be creation of a varying 
boundary condition at the surface of the stent, based on experimental data.  This would most 
accurately mimic the true elution profile; however, no literature values could be found for the 
such a profile for the full 2 year simulation time period. 
  As an alternative to modeling a metallic stent with a surface polymer coating, we 
determined that simulation of a biodegradable, polymeric stent was optimal for solution in 
FiDAP.  These nonpermanent stent have the potential to remain in situ for a predicted period of 
time, and because there is a decreasing need for a permanent prosthesis after 6 months
1, 
polymeric stents are an optimal solution to restinosis.  Two polymers commonly used in 
Rapamycin-eluting stents are polyethylenevinylacetate (PEVA) and polybutylmethacrylate 
(PBMA).
7 Two other polymers currently under clinical investigation are polylactide (PLA) and 
poly(lactide-co-glycolide) (PLG). 
 
Drug  Diffusion (cm
2/s) from PLA Stent
1 Diffusion (cm
2/s) from PLG Stent
1
Paclitaxel  4.9 x 10
-12 5.7 x 10
-9
Rapamycin  3.1 x 10
-12 4.5 x 10
-11
Table C.3: Different drug diffusitivities depending on polymer type. 
 
The relatively wide range of diffusivity values found simply by modifying the type of 
polymer demonstrates the complexity of choosing appropriate diffusivity values; the nature of 
the polymer in which Rapamycin is immobilized should be a concern for future modeling and 
design of drug-eluting stents. 
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